Legal & General Group PLC Summit Therapeutics Inc. Transaction History

Legal & General Group PLC

$368 Billion
Q4 2024

A detailed history of Legal & General Group PLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 10,061 shares of SMMT stock, worth $182,908. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,061

Previous 9,719 3.52%

Holding current value

$182,908

Previous $212,000 15.57%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 13, 2025	BUY	$17.52 - $23.46 $5,991 - $8,023	342 Added 3.52%	10,061 $179,000
Q3 2024 Feb 28, 2025	SELL	$6.89 - $31.93 $2,356 - $10,920	-342 Reduced 3.4%	9,719 $212,000
Q3 2024 Nov 14, 2024	SELL	$6.89 - $31.93 $127,561 - $591,152	-18,514 Reduced 65.58%	9,719 $212,000
Q2 2024 Aug 14, 2024	SELL	$2.39 - $10.92 $213,630 - $976,084	-89,385 Reduced 76.0%	28,233 $220,000
Q1 2024 May 14, 2024	SELL	$2.55 - $5.07 $3,534 - $7,027	-1,386 Reduced 1.16%	117,618 $486,000
Q4 2023 Feb 15, 2024	BUY	$1.67 - $2.83 $1,518 - $2,572	909 Added 0.77%	119,004 $310,000
Q3 2023 Nov 14, 2023	BUY	$1.54 - $2.42 $11,519 - $18,101	7,480 Added 6.76%	118,095 $220,000
Q2 2023 Aug 14, 2023	BUY	$1.32 - $2.81 $146,011 - $310,828	110,615 New	110,615 $277,000
Q2 2022 Aug 22, 2022	SELL	$0.92 - $2.38 $2,548 - $6,592	-2,770 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$4.83 - $8.27 $1,888 - $3,233	391 Added 16.44%	2,770 $14,000
Q2 2021 Aug 12, 2021	BUY	$5.15 - $8.46 $12,251 - $20,126	2,379 New	2,379 $18,000

Others Institutions Holding SMMT

# of Institutions

233

Shares Held

83.1M

Call Options Held

1.66M

Put Options Held

2.56M

View Full List

About Summit Therapeutics Inc.

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.66B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

More about SMMT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Account

Legal & General Group PLC Summit Therapeutics Inc. Transaction History